Premium
The Renin‐Angiotensin System: A Therapeutic Target in Atrial Fibrillation
Author(s) -
PATLOLLA VISHNU,
ALSHEIKHALI ALAWI A.,
ALAHMAD AMIN M.
Publication year - 2006
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.2006.00477.x
Subject(s) - medicine , atrial fibrillation , pathogenesis , heart failure , cardiology , renin–angiotensin system , blockade , cardioversion , receptor , blood pressure
There is growing evidence to suggest a role for the renin‐angiotensin system (RAS) in the pathogenesis of atrial fibrillation (AF). Experimental animal data suggest RAS‐dependent mechanisms for the development of a structural and electrophysiologic substrate for AF. This is consistent with clinical data demonstrating the effectiveness of RAS blockade in preventing new‐onset or recurrent AF in a variety of patient populations including patients with hypertension and left ventricular hypertrophy, congestive heart failure, and those undergoing electrical cardioversion for AF. This review summarizes experimental and clinical evidence to date relating to the role of RAS in the pathogenesis of AF, and the efficacy of its inhibition in managing this common arrhythmia.